Polarean Imaging reports on phase III lung trials

By AuntMinnie.com staff writers

January 30, 2020 -- Polarean Imaging is touting the results of two phase III clinical trials for its drug-device combination that uses hyperpolarized xenon-129 (Xe-129) gas with MRI to visualize and quantify regional lung function.

When polarized with Polarean's system, Xe-129 enables functional, regional, and quantitative MR imaging of the lungs. Patients inhale Xe-129 as a gas during a 10-second breath-hold procedure. During clinical trials, ventilation in zones of interest was quantified and compared with images, similarly quantified, from a different imaging modality.

Both clinical trials met their primary end points within the prospectively defined equivalence margin (± 14.7%) when compared with a reference standard approved by the U.S. Food and Drug Administration (FDA), 133-xenon scintigraphy imaging.

Polarean plans to submit a new drug application (NDA) to the FDA in the third quarter of this year.


Copyright © 2020 AuntMinnie.com
 

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: